Tenecteplase
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | TNKASE | — | 2025-02-28 | fda.gov ↗ |
| Approved | EU (EMA) | Metalyse | — | 2001-02-23 | europa.eu ↗ |
| Approved | US (FDA) | TNKASE | — | 2000-06-02 | fda.gov ↗ |
Trials 111 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT06696131 | Sep 2026 → Jan 2028 expected | intracerebral hemorrhage | Gaurav Gupta, MD | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07641998 | Jun → Dec 2026 expected | hemorrhagic stroke | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06801054 | Jul 2025 → Jun 2026 overdue | ischemic stroke | Memorial Hermann Health System | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06814964 | Mar → May 2025 overdue | intracerebral hemorrhage | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06668441 | Nov 2024 → Jan 2025 | hemorrhagic disease, intracerebral hemorrhage | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00431379 | Feb 2007 → Nov 2008 | acute respiratory distress syndrome | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 218 trials | ||||||
| Phase 2 | NCT07375966 | Mar 2026 → Dec 2027 expected | ischemic stroke | General Hospital of Shenyang Military Region | Recruiting | No outcome recorded |
| Phase 2 | NCT07375953 | Mar 2026 → Dec 2027 expected | ischemic stroke | General Hospital of Shenyang Military Region | Recruiting | No outcome recorded |
| Phase 2 | NCT06904911 | Dec 2025 → Sep 2026 expected | large artery stroke | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 2 | NCT06781385 | Sep 2025 → Sep 2026 expected | ischemic stroke | Wake Forest University Health Sciences | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT05580822 | Jan 2023 → Dec 2024 | basilar artery occlusion | First Hospital of China Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05172934 | Mar 2022 → Sep 2023 | ischemic stroke | ProMedica Health System | Completed | No outcome recorded |
| Phase 2 | NCT05189509 | Feb → Sep 2022 | ischemic stroke | General Hospital of Shenyang Military Region | Completed | No outcome recorded |
| Phase 2 | NCT04516993 | Sep 2021 → Sep 2023 | stroke disorder | Huashan Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05281549 | May 2021 → Jan 2022 | ischemic stroke | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04505592 | Sep 2020 → Mar 2022 | COVID-19, acute respiratory distress syndrome | Hooman Poor | Completed | No outcome recorded |
| Phase 2 | NCT04086147 | Dec 2019 → Dec 2021 | stroke disorder | Huashan Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04676659 | May 2018 → May 2020 | ischemic stroke | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03340493 | Dec 2017 → Jul 2019 | ischemic stroke | Neuroscience Trials Australia | Completed | No outcome recorded |
| Phase 2 | NCT02388061 | Mar 2015 → Oct 2017 | ischemic stroke | Neuroscience Trials Australia | Completed | No outcome recorded |
| Phase 2 | NCT01654445 | Jul 2012 → Jul 2014 | ischemic stroke | University of Calgary | Completed | No outcome recorded |
| Phase 2 | NCT01472926 | Dec 2011 → Dec 2013 | ischemic stroke | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| Phase 2 | NCT02101606 | Oct 2009 → Nov 2017 | brain ischemia, cerebral infarction | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT00222651 | Jul 2004 → Jul 2006 | pulmonary embolism | University Of Perugia | Terminated | No outcome recorded |
| Phase 2/39 trials | ||||||
| Phase 2/3 | NCT07302854 | Dec 2025 → Dec 2028 expected | cerebral artery occlusion, ischemic stroke | Xiang Luo | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06949228 | Jul 2025 → May 2028 expected | ischemic stroke | ProMedica Health System | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05892510 | Jun 2024 → Aug 2027 expected | ischemic stroke | University of Melbourne | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05657470 | Mar 2023 → Jun 2025 | ischemic stroke | General Hospital of Shenyang Military Region | Completed | No outcome recorded |
| Phase 2/3 | NCT05684172 | Jan → Aug 2023 | cerebral artery occlusion, ischemic stroke | The First Affiliated Hospital of University of Science and Technology of China | Completed | No outcome recorded |
| Phase 2/3 | NCT04733742 | May 2022 → Dec 2024 | ischemic stroke | Xinqiao Hospital of Chongqing | Completed | No outcome recorded |
| Phase 2/3 | NCT05105633 | Nov 2021 → May 2028 expected | basilar artery occlusion | University of Melbourne | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02180204 | Jan 2015 → Jun 2020 | ischemic stroke | Reza Behrouz, DO | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT00121446 | Jul 2003 → ? | myocardial infarction | University of Alberta | Completed | No outcome recorded |
| Phase 356 trials | ||||||
| Phase 3 | NCT07621796 | Jan 2027 → Jan 2032 expected | ischemic stroke | Hackensack Meridian Health | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07606807 | Aug 2026 → Dec 2028 expected | ischemic stroke | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT07668323 | Jul 2026 → Jul 2028 expected | ischemic stroke, vascular occlusion disorder | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07603440 | Jun 2026 → Jul 2029 expected | stroke disorder | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07540416 | May 2026 → Dec 2027 expected | ischemic stroke | The First Affiliated Hospital of Zhengzhou University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07475949 | Apr 2026 → Dec 2028 expected | ischemic stroke | First Affiliated Hospital of Guangxi Medical University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07471256 | Mar 2026 → Dec 2028 expected | intracerebral hemorrhage | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07476898 | Mar 2026 → Jul 2028 expected | stroke disorder | First Hospital of China Medical University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07471282 | Mar 2026 → Dec 2028 expected | stroke disorder | Chuansheng Zhao | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07361302 | Feb 2026 → Oct 2027 expected | ischemic stroke | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 3 | NCT07357987 | Jan 2026 → Sep 2027 expected | cerebral artery occlusion, ischemic stroke | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07253181 | Jan 2026 → Mar 2028 expected | cerebral artery occlusion, ischemic stroke | Xuanwu Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 3 | NCT06658197 | Dec 2025 → Dec 2026 expected | intracranial thrombosis, ischemic stroke | Xuanwu Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 3 | NCT07201688 | Nov 2025 → Sep 2027 expected | ischemic stroke | CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06994975 | Nov 2025 → Mar 2028 expected | ischemic stroke | Huashan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07168278 | Nov 2025 → Mar 2028 expected | cerebral artery occlusion, ischemic stroke | The First Affiliated Hospital of University of Science and Technology of China | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06987305 | Oct 2025 → Oct 2027 expected | ischemic stroke | Xinqiao Hospital of Chongqing | Recruiting | No outcome recorded |
| Phase 3 | NCT07073469 | Sep 2025 → Aug 2027 expected | ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07092709 | Aug 2025 → Sep 2028 expected | ischemic stroke | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT07047014 | Jul 2025 → Mar 2027 expected | ischemic stroke, vascular occlusion disorder | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06414499 | Jul 2025 → Jul 2026 overdue | cerebrovascular disorder | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06954155 | May 2025 → Feb 2027 expected | ischemic stroke | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06868511 | Apr 2025 → Mar 2027 expected | intracerebral hemorrhage | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06841978 | Mar 2025 → Jun 2027 expected | ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06841965 | Mar 2025 → Jun 2027 expected | ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06749834 | Jan 2025 → Dec 2026 expected | ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 3 | NCT06352632 | Sep 2024 → Sep 2034 expected | stroke disorder | The George Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT06221371 | Jan 2024 → Oct 2025 | ischemic stroke | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 3 | NCT06196320 | Jan 2024 → Sep 2025 | ischemic stroke | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05657444 | Mar 2023 → Mar 2025 | ischemic stroke | General Hospital of Shenyang Military Region | Completed | No outcome recorded |
| Phase 3 | NCT05499832 | Mar 2023 → Oct 2025 | ischemic stroke | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 3 | NCT05657457 | Mar 2023 → May 2025 | ischemic stroke | General Hospital of Shenyang Military Region | Terminated | No outcome recorded |
| Phase 3 | NCT05701956 | Mar 2023 → Feb 2025 | basilar artery occlusion, stroke disorder | The First Affiliated Hospital of University of Science and Technology of China | Completed | No outcome recorded |
| Phase 3 | NCT05634382 | Dec 2022 → Nov 2024 | ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 3 | NCT05745259 | Oct 2022 → Nov 2023 | ischemic stroke | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05199194 | May 2022 → Jul 2026 overdue | ischemic stroke | Hospital Moinhos de Vento | Recruiting | No outcome recorded |
| Phase 3 | NCT05199662 | Jan 2022 → Jul 2026 overdue | ischemic stroke | Hospital Moinhos de Vento | Recruiting | No outcome recorded |
| Phase 3 | NCT05141305 | Jan 2022 → Jan 2024 | ischemic stroke | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03998319 | Oct 2021 → Dec 2024 overdue | ST-elevation myocardial infarction | University of Sydney | Recruiting | No outcome recorded |
| Phase 3 | NCT04915729 | Jun 2021 → Oct 2023 | stroke disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT04454788 | Aug 2020 → Jul 2024 | ischemic stroke | University of Melbourne | Terminated | No outcome recorded |
| Phase 3 | NCT03785678 | Mar 2019 → Feb 2023 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02814409 | Dec 2016 → Aug 2023 | ischemic stroke | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| Phase 3 | NCT02398656 | Apr 2015 → Jan 2024 | ischemic stroke | University of Calgary | Completed | No outcome recorded |
| Phase 3 | NCT00680628 | May 2008 → May 2012 | pulmonary embolism | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 3 | NCT00623623 | Mar 2008 → Sep 2012 | myocardial infarction | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00639743 | Nov 2007 → Jul 2012 | pulmonary embolism | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT00396318 | Dec 2006 → Jun 2008 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00396253 | Nov 2006 → Oct 2008 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00395876 | Nov 2006 → Jun 2008 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00396032 | Oct 2006 → Dec 2008 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00157261 | Jan 2004 → Jun 2006 | cardiac arrest | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 3 | NCT00148460 | Mar 2001 → Feb 2006 | myocardial infarction | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02181998 | Jul 2000 → Aug 2002 | myocardial infarction | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02181985 | May 2000 → Apr 2001 | myocardial infarction | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02182011 | May 2000 → Jun 2001 | myocardial infarction | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 418 trials | ||||||
| Phase 4 | NCT07641231 | May 2026 → May 2028 expected | ST-elevation myocardial infarction | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07203625 | Jan 2026 → Dec 2027 expected | basilar artery occlusion, ischemic stroke | Xuanwu Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 4 | NCT07294209 | Dec 2025 → Dec 2028 expected | stroke disorder | Southwest Hospital, China | Recruiting | No outcome recorded |
| Phase 4 | NCT06571149 | Mar 2025 → Jan 2029 expected | ischemic stroke | Insel Gruppe AG, University Hospital Bern | Recruiting | No outcome recorded |
| Phase 4 | NCT06115070 | Mar 2025 → Dec 2027 expected | ischemic stroke, thrombotic disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06769256 | Jan 2025 → Dec 2027 expected | ST-elevation myocardial infarction | Henan Institute of Cardiovascular Epidemiology | Recruiting | No outcome recorded |
| Phase 4 | NCT06010628 | Feb 2024 → Dec 2026 expected | ischemic stroke | General Hospital of Shenyang Military Region | Recruiting | No outcome recorded |
| Phase 4 | NCT05752916 | Jun 2023 → Oct 2025 | ischemic stroke | Xuanwu Hospital, Beijing | Completed | No outcome recorded |
| Phase 4 | NCT05624190 | Feb 2023 → Jul 2024 | ischemic stroke | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT06498323 | Aug 2022 → Aug 2025 overdue | ischemic stroke, thrombotic disease | Mahidol University | Recruiting | No outcome recorded |
| Phase 4 | NCT04752631 | Mar 2021 → Jul 2022 | ischemic stroke | General Hospital of Shenyang Military Region | Completed | No outcome recorded |
| Phase 4 | NCT04558125 | Sep 2020 → Jul 2021 | COVID-19, pulmonary embolism | Cedars-Sinai Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT02777580 | Aug 2017 → Oct 2022 | myocardial infarction | KU Leuven | Completed | No outcome recorded |
| Phase 4 | NCT02835534 | May 2016 → Oct 2019 | ST-elevation myocardial infarction | CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02592694 | Oct 2015 → Oct 2017 | ST-elevation myocardial infarction | Xijing Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02592720 | Oct 2015 → Oct 2017 | acute coronary syndrome | Xijing Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00359918 | Aug 2006 → Aug 2009 | myocardial infarction | Holger Thiele | Completed | No outcome recorded |
| Phase 4 | NCT00168792 | Nov 2003 → Jul 2006 | myocardial infarction | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT07094763 | Nov 2025 → Oct 2027 expected | ischemic stroke | The First Affiliated Hospital of University of Science and Technology of China | Recruiting | No outcome recorded |
| — | NCT06559436 | Oct 2024 → Sep 2026 expected | ischemic stroke | The First Affiliated Hospital of University of Science and Technology of China | Recruiting | No outcome recorded |
| — | NCT04201964 | Dec 2019 → Jun 2026 overdue | ischemic stroke | Huisheng Chen | Recruiting | No outcome recorded |
| — | NCT04202458 | Dec 2019 → Aug 2021 | ischemic stroke | General Hospital of Shenyang Military Region | Completed | No outcome recorded |
Also used as a comparator or background therapy in 23 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT04071613 Comparator | Jun 2019 → Nov 2021 | ischemic stroke | Melbourne Health | Completed | No outcome recorded |
| Phase 2 | NCT02338466 Comparator | Jul 2016 → Jul 2018 | cerebral arterial disease | University Hospital Center of Martinique | Withdrawn | No outcome recorded |
| Phase 2 | NCT00604695 Comparator | Jul 2008 → Nov 2011 | acute myocardial infarction | C. Michael Gibson, MS, MD | Completed | No outcome recorded |
| Phase 2 | NCT00252239 Comparator | Nov 2005 → Mar 2009 | ischemic stroke | University of Virginia | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01580618 Comparator | Jan 2008 → Sep 2011 | — | Kaiser Permanente | Terminated | No outcome recorded |
| Phase 315 trials | ||||||
| Phase 3 | NCT07687056 Comparator | Jun 2026 → Dec 2030 expected | ischemic stroke | University of Calgary | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07369999 Background | Feb 2026 → Mar 2029 expected | stroke disorder | Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06878066 Comparator | Mar 2025 → Dec 2028 expected | intracerebral hemorrhage, ischemic stroke | Guri Hagberg | Recruiting | No outcome recorded |
| Phase 3 | NCT06320431 Comparator | Sep 2024 → Sep 2030 expected | ischemic stroke | University of Calgary | Recruiting | No outcome recorded |
| Phase 3 | NCT05827042 Comparator | May 2023 → Jun 2026 overdue | basilar artery occlusion, stroke disorder | The First Affiliated Hospital of University of Science and Technology of China | Recruiting | No outcome recorded |
| Phase 3 | NCT04965038 Comparator | Oct 2022 → Mar 2026 | central retinal artery occlusion | University Hospital Tuebingen | Terminated | No outcome recorded |
| Phase 3 | NCT05626972 Comparator | May 2022 → May 2023 | ischemic stroke | Hospital Universitari Vall d'Hebron Research Institute | Unknown | No outcome recorded |
| Phase 3 | NCT05601999 Comparator | Sep 2021 → Oct 2024 | ST-elevation myocardial infarction | AO GENERIUM | Unknown | No outcome recorded |
| Phase 3 | NCT04797013 Comparator | Jun 2021 → May 2022 | ischemic stroke | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04526951 Comparator | Oct 2020 → Jun 2025 | central retinal artery occlusion | Oslo University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03889249 Comparator | Dec 2019 → Apr 2022 | intracranial thrombosis, ischemic stroke | University of Calgary | Completed | No outcome recorded |
| Phase 3 | NCT03854500 Comparator | Oct 2019 → Sep 2021 | ischemic stroke | Haukeland University Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT03181360 Comparator | Jun 2017 → Dec 2021 | ischemic stroke | University Hospital of North Norway | Unknown | No outcome recorded |
| Phase 3 | NCT02301910 Comparator | May 2014 → Dec 2016 | myocardial infarction | Supergene, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01949948 Comparator | Sep 2012 → Dec 2016 | ischemic stroke | Lars Thomassen | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00257309 Comparator | Apr 2005 → Feb 2008 | acute myocardial infarction | Spanish Society of Cardiology | Terminated | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06833827 Comparator | Feb 2025 → Jan 2028 expected | pulmonary embolism | Leiden University Medical Center | Recruiting | No outcome recorded |
| — | NCT06241677 Comparator | Apr 2024 → Dec 2028 expected | ischemic stroke | Chinese University of Hong Kong | Recruiting | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 138 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tenecteplase | “The TRACE III trial showed that for patients with large arterial occlusion presenting 4.5-24 hours of symptom occurrence and a salvageable penumbra on perfusion imaging,...” PMID 41974576 ↗ Apr 2026123“Standard reperfusion treatment for high-risk PE patients is thrombolytic therapy, typically consisting of Alteplase, Urokinase, or Tenecteplase, with the idea of accelerated...” NCT06833827 ↗ “Patients with STEMI (<3 h after symptom onset) were randomized to either pre-hospital-initiated facilitated PCI using tenecteplase (Group A; n = 81) or primary PCI (Group B; n...” PMID 21700245 ↗ Jun 2011 “Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in...” NCT02181985 ↗ “Tenecteplase (TNK), a novel thrombolytic agent with favorable pharmacokinetic profiles, and butylphthalide (NBP), a multi-targeted neuroprotective drug, have shown promising...” NCT07369999 ↗ “This study aims to evaluate the efficacy and safety of tenecteplase (TNK) intravenous thrombolysis within the extended time window (4.5 to 24 hours) in patients with acute...” NCT07094763 ↗ “In contrast, tenecteplase, a third-generation fibrinolytic agent, exhibits higher fibrin specificity and a longer half-life, which may enhance thrombolytic efficiency and...” NCT06814964 ↗ “while tenecteplase (TNK), a third-generation thrombolytic agent, with greater potency in lysing platelet-rich clots and heightened specificity for fibrin may improve...” NCT06868511 ↗ “Tenecteplase (TNK) possesses several pharmacological characteristics superior to conventional alteplase (rt-PA), with well-established safety and efficacy profile in Caucasians.” PMID 34429364 ↗ Aug 2021 “Tenecteplase (rhTNK-tPA), a third-generation specific fibrinolytic agent, is used for intravenous thrombolysis in acute ischemic stroke and has higher fibrin specifc.” NCT06668441 ↗ “The current trial aimed to investigate the safety and efficacy of intravenous tenecteplase (TNK) plus Dl-3-n-Butylphthalide (NBP) in AIS within 4.5 to 6 h of onset.” PMID 38238620 ↗ Jan 2024 “Agent options: alteplase (rt-PA) at 0.225 mg/kg (maximum 22.5 mg) or tenecteplase (TNK) at 0.0625 mg/kg (maximum 6.25 mg), infused over 15-30 minutes.” NCT07668323 ↗ “Patients will receive intravenous alteplase (0.9mg/kg, maximum 90mg) or tenecteplase (0.25mg/kg, maximum 25mg) before endovascular thrombectomy.” NCT05827042 ↗ “intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg)” NCT06841965 ↗ “intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg)” NCT06749834 ↗ “The purpose of this study is to evaluate the efficacy and safety of intravenous tenecteplase (0.25 mg/kg) compared with standard therapy” NCT06414499 ↗ “both drugs (Alteplase (ALP) and Tenecteplase (TNK)) are approved drugs for the indication AIS with similar efficacy and safety profile.” NCT06878066 ↗ “Patients in the tenecteplase group were administered a 0.25mg/kg dose as a bolus over 5-10 seconds, followed by a 2 mL saline flush.” NCT06994975 ↗ “Tenecteplase (TNK), a third-generation thrombolytic with high fibrin specificity and superior activity against platelet-rich clots.” NCT07471256 ↗ “Tenecteplase, a recombinant human tenecteplase tissue-type plasminogen activator, is a genetically modified variant of alteplase.” PMID 39435713 ↗ Oct 2024 “Intravenous thrombolysis with recombinant tissue-type plasminogen activator (rt-PA，alteplase) or TNK-tPA (Tenecteplase，Metalyse)” NCT05634382 ↗ “Participants will receive intravenous tenecteplase at a dose of 0.25 mg/kg (max 25 mg) administered as a bolus after enrollment.” NCT07168278 ↗ “Intravenous administration of Tenecteplase (0.25 mg/kg, maximum 25 mg) followed by mechanical thrombectomy” NCT07603440 ↗ “Intracoronary cocktail (tirofiban, bivalirudin, tenecteplase) injection combined with thrombus aspiration” NCT02592694 ↗ “Tenecteplase (TNK) in the Treatment of Intracerebral Hemorrhage (ICH)” NCT06696131 ↗ “rhTNK-tPA（Tenecteplase）dose: 0.125 mg/kg, maximum dose: 12.5mg.” NCT07302854 ↗ “cocktail (tirofiban, bivalirudin, tenecteplase)” NCT02592720 ↗ “intravenous Tenecteplase(0.25mg/kg” NCT06115070 ↗ “intravenous Tenecteplase(0.25mg/kg” NCT06841978 ↗ “Intra-arterial Tenecteplase” NCT07357987 ↗ |
| Known as | Metalyse | “Intravenous thrombolysis with recombinant tissue-type plasminogen activator (rt-PA，alteplase) or TNK-tPA (Tenecteplase，Metalyse)” NCT05634382 ↗2“Thrombolysis Using Tenecteplase (Metalyse®) in Cardiac Arrest - The TROICA Trial” NCT00157261 ↗ |
| Known as | Mingfule | “Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Recombinant Human TNK Tissue-Type Plasminogen Activator for Injection (rhTNK-tPA,...” NCT07201688 ↗ |
| Known as | rhTNK-tPA | “A Phase I Pilot Clinical Trial of Dose Escalation With Stereotactic-Guided Intraventricular Thrombolysis Using Tenecteplase (rhTNK-tPA) for Intraventricular Hemorrhage.” NCT06814964 ↗10“Tenecteplase (rhTNK-tPA), a third-generation specific fibrinolytic agent, is used for intravenous thrombolysis in acute ischemic stroke and has higher fibrin specifc.” NCT06668441 ↗ “Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg)” NCT07606807 ↗ |
| Known as | TNK | “If patients are randomized and assigned to receive intra-arterial tenecteplase thrombolysis, tenecteplase will be injected according to protocol, proceeding to inject TNK...” NCT05684172 ↗28“The TRACE III trial showed that for patients with large arterial occlusion presenting 4.5-24 hours of symptom occurrence and a salvageable penumbra on perfusion imaging,...” PMID 41974576 ↗ Apr 2026 “The primary objective of this study is to explore the efficacy and safety of the dose of 0.25 mg/kg tenecteplase (TNK) in Chinese acute ischemic stroke (AIS) patients without...” NCT06994975 ↗ “The newer thrombolytic agent, tenecteplase (TNK), offers practical advantages-including single bolus administration, a longer half-life, and potentially higher fibrin...” NCT07375966 ↗ “Tenecteplase (TNK), a novel thrombolytic agent with favorable pharmacokinetic profiles, and butylphthalide (NBP), a multi-targeted neuroprotective drug, have shown promising...” NCT07369999 ↗ “This study aims to evaluate the efficacy and safety of tenecteplase (TNK) intravenous thrombolysis within the extended time window (4.5 to 24 hours) in patients with acute...” NCT07094763 ↗ “while tenecteplase (TNK), a third-generation thrombolytic agent, with greater potency in lysing platelet-rich clots and heightened specificity for fibrin may improve...” NCT06868511 ↗ “The study objective is to evaluate the safety and efficacy of Intra arterial (IA) Tenecteplase (TNK) as an adjunctive therapy in acute ischemic stroke (AIS) patients” NCT06949228 ↗ “The current trial aimed to investigate the safety and efficacy of intravenous tenecteplase (TNK) plus Dl-3-n-Butylphthalide (NBP) in AIS within 4.5 to 6 h of onset.” PMID 38238620 ↗ Jan 2024 “patients received an initial dose of intraluminal tenecteplase (TNK) (up to 2 mg), a second dose of tenecteplase if indicated, and a third placebo (PBO) dose.” PMID 21111365 ↗ Dec 2010 “Agent options: alteplase (rt-PA) at 0.225 mg/kg (maximum 22.5 mg) or tenecteplase (TNK) at 0.0625 mg/kg (maximum 6.25 mg), infused over 15-30 minutes.” NCT07668323 ↗ “both drugs (Alteplase (ALP) and Tenecteplase (TNK)) are approved drugs for the indication AIS with similar efficacy and safety profile.” NCT06878066 ↗ “Tenecteplase (TNK), a third-generation thrombolytic with high fibrin specificity and superior activity against platelet-rich clots.” NCT07471256 ↗ “Intravenous administration of tenecteplase (TNK) at 0.25 mg/kg for a maximum dose of 25 mg.” NCT07621796 ↗ “Tenecteplase (TNK) in the Treatment of Intracerebral Hemorrhage (ICH)” NCT06696131 ↗ “the ANGEL-TNK, POST-TNK, and DATE studies (using tenecteplase, TNK)” NCT07471282 ↗ “Drug: Tenecteplase (TNK) for intrahematoma administration.” NCT07641998 ↗ “Drug: Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)” NCT07253181 ↗ “Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)” NCT02101606 ↗ “Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)” NCT07475949 ↗ “Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)” NCT07092709 ↗ “Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)” NCT07073469 ↗ “90 min posttenecteplase (TNK) in the PI arm” PMID 24916050 ↗ Jun 2014 “thrombolytic tenecteplase (TNK, 0.25mg/kg)” NCT05105633 ↗ “Intravenous Tenecteplase (IV TNK)” NCT06801054 ↗ “Intravenous tenecteplase (TNK)” NCT04454788 ↗ “IA Tenecteplase (TNK)” NCT05172934 ↗ “Tenecteplase (tNK)” NCT02398656 ↗ “TNK (Tenecteplase)” NCT01580618 ↗ |
| Known as | TNK-tissue-type plasminogen activator | “Tenecteplase (TNK-tissue-type plasminogen activator) compared with alteplase is easier to administer” PMID 25677596 ↗ Feb 2015 |
| Known as | tNK-TPA | “Intravenous thrombolysis with recombinant tissue-type plasminogen activator (rt-PA，alteplase) or TNK-tPA (Tenecteplase，Metalyse)” NCT05634382 ↗ |
| Known as | TNKase | “optimal pharmacologic therapy (prompt administration of tenecteplase (TNKase) and enoxaparin)” NCT00121446 ↗1“1. TNKase (0.25 mg/kg) bolus Other names: Tenecteplase, TNK” NCT04558125 ↗ |
| Action | Activate | “selectively activating plasminogen within local thrombi” NCT07471256 ↗ |
| Modality | Protein / enzyme biologic | “the thrombolytic tenecteplase, a fibrin-specific recombinant tissue plasminogen activator” PMID 21111365 ↗ Dec 2010 |
| Route | Intravenous | “Study drug application, as a single IV bolus over 5-10 seconds, should be done immediately after the first vasopressor application during the ALS-CPR procedure.” NCT00157261 ↗ |